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Background: The purpose of this study was to investigate some of the possible mechanisms underlying the
protective effects of a dipeptidyl peptidase IV (DPP-IV) inhibitor, sitagliptin, on pancreatic tissue in an animal model
of type 2 diabetes mellitus (T2DM), the Zucker Diabetic Fatty (ZDF) rat, focusing on glycaemic, insulinic and lipidic
profiles, as well as, on apoptosis, inflammation, angiogenesis and proliferation mediators.
Methods: Male obese diabetic ZDF (fa/fa) rats, aged 20 weeks, were treated with sitagliptin (10 mg/kg bw/day)
during 6 weeks and compared to untreated diabetic and lean control littermates. Metabolic data was evaluated at
the beginning and at the end of the treatment, including glycaemia, HbA1c, insulinaemia, HOMA-beta and TGs.
Endocrine and exocrine pancreas lesions were assessed semiquantitatively by histopathological methods. Pancreas
gene (mRNA) and protein expression of mediators of apoptotic machinery, inflammation and angiogenesis/
proliferation (Bax, Bcl2, IL-1β, VEGF, PCNA and TRIB3) were analyzed by RT-qPCR and/or by immunohistochemistry.
Results: Sitagliptin treatment for 6 weeks (between 20 and 26 week-old) was able to significantly (p < 0.001)
ameliorate all the metabolic parameters, by preventing the increase in blood glucose and in serum TGs contents
(16.54% and 37.63%, respectively, vs untreated), as well as, by preventing the decrease in serum insulin levels and in
the functional beta cells capacity accessed via HOMA-beta index (156.28% and 191.74%, respectively, vs untreated).
Sitagliptin-treated diabetic rats presented a reduced pancreas Bax/Bcl2 ratio, suggestive of an antiapoptotic effect;
in addition, sitagliptin was able to completely reduce (p < 0.001) the pancreas overexpression of IL-1β and TRIB3
found in the untreated diabetic animals; and promoted a significant (p < 0.001) overexpression of VEGF and PCNA.
Conclusion: In this animal model of obese T2DM (the ZDF rat), sitagliptin prevented β-cell dysfunction and
evolution of pancreatic damage. The protective effects afforded by this DPP-IV inhibitor may derive from improvement
of the metabolic profile (viewed by the amelioration of glucose and TGs levels and of insulin resistance) and from
cytoprotective properties, such as antiapoptotic, anti-inflammatory, pro-angiogenic and pro-proliferative.
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Type 2 diabetes mellitus (T2DM) prevalence and incidence
is rapidly increasing worldwide; it is predicted, according to
the latest estimates of the World Health Organization
(WHO), that diabetes will be the 7th leading cause of death
in 2030 [1]. T2DM is a chronic disease leading to macro-
and microvascular complications, which results in severe
illness and premature death, with elevated personal and
economic costs [2,3].
The central features of T2DM are a defect in insulin
resistance and/or insulin secretion, which lead to hyper-
glycaemia; disruption of the normal relationship between
insulin sensitivity and pancreatic β-cell function is a hall-
mark of T2DM progression [4]. In fact, degeneration of
Langerhans islets with β-cell loss is secondary to insulin
resistance and is regarded as the most important lesion
for progression of the disease [5,6]. As β-cell function
declines, the impairment of insulin action becomes more
important. Hyperglycaemia, per se, may have a detrimental
effect on secretory function, − “glucotoxicity” –, which in-
duces increased apoptosis in pancreatic islets; in addition,
the abnormal lipid profile commonly observed in these
subjects may be associated with functional impairment of
the islet – “lipotoxicity” [5-8].
Current knowledge adds further complexity in the picture
of T2DM pathogenesis by including the role of incretin
hormones. Incretins [gastric inhibitory polypeptide (GIP)
and glucagon-like peptide-1 (GLP-1)] are peptide hormones
secreted in the gastrointestinal mucosa after meal ingestion.
These are released in response to oral glucose intake and
are able to attain physiological concentrations causing insu-
lin release, which is called the “incretin effect” [9-12]. GLP-
1 acts in a positive way on the β and δ cells, whereas GIP
acts preferentially on α and β cells. These peptides are
almost undetectable during fasting and exist only in high
concentrations in the postprandial state, since they are rap-
idly metabolized [13] by the ubiquitous enzyme, dipeptidyl
peptidase-IV (DPP-IV), to inactive metabolites, which are
eliminated by urine [14]. The incretin effect is responsible
for about 60% of the secretion of postprandial insulin,
which is decreased in T2DM [15]. In these patients, the
incretin effect is stifled, producing an “incretin defect”. This
condition occurs as a result of reduced secretion of GLP-1,
accelerated metabolism of GLP-1 and GIP, as well as
defective response to both hormones, particularly to the
insulinotropic effect of GIP [16,17]. The key mechanisms
by which these factors exert their action on β-cells are not
yet completely elucidated, but currently lie on metabolic
processes such as apoptosis and inflammation, among
others putatively involved.
Low-grade inflammation has been viewed as a major
player in insulin resistance development and T2DM evo-
lution; indeed, hyperglycaemia seems to induce the pro-
duction of acute phase reactants from the adipose tissue,while obesity, present in many diabetic patients, is in itself,
characterized as a state of low grade inflammation [18].
T2DM is found to display increased concentrations of
C-reactive protein (CRP) and pro-inflammatory cytokines,
such as tumor necrosis factor-α (TNF-α) and interleukins
1 and 6 (IL-1, IL-6), which are implicated in instigating
metabolic insulin resistance [19]. However, it is not still
clear which is the cause and/or the consequence. A recent
study by Martin-Cordero et al. [20] using obese fa/fa obese
Zucker rats confirmed the presence of augmented inflam-
matory markers (IL-6 and CRP) in metabolic syndrome
(MS), together with increased noradrenaline contents; the
authors postulate that those results may reflect a defect-
ive regulation of the negative inflammatory/stress feed-
back loop under those circumstances, suggesting that MS
could be either the cause or the consequence of diabetes
associated with obesity.
Additionally, although the loss of β -cell mass is not
yet completely clarified, apoptosis seems to be involved,
as previously observed in pancreas at autopsy and isolated
islets from people with T2DM [21,22]. Based on these as-
sumptions, it is becoming clear that T2DM management,
namely by using pharmacological agents, must envision
not only glycaemic control but also, and particularly, the
mechanisms behind progression of pancreatic deterioration
and underlying evolutional complications. In fact, T2DM
therapeutics should be able to preserve β-cell mass as the
mainstay of disease control, by addressing the mechanisms
implicated in diabetic pathogenesis, including apoptosis, in-
flammation or even an added capacity for cell proliferation.
Enhancing the incretin effect is now a possible thera-
peutic target in T2DM, using GLP-1 analogues or DPP-IV
inhibitors. Sitagliptin belongs to a class of oral antidiabetic
drugs, the gliptins, which inhibit the enzyme DPP-IV that
degrades incretins, prolonging the physiological actions
of GLP-1 [23,24]. GLP-1, a prominent active compound
of the incretin family, modulates many processes in pancre-
atic islet: it potentiates insulin synthesis and secretion [25],
inhibits glucagon secretion [26], increases islet cell prolifer-
ation, and decreases cell apoptosis [27,28]. Our group has
previously shown that sitagliptin is able to ameliorate dys-
metabolism, insulin resistance, inflammation and oxidative
stress in an animal model of T2DM, the Zucker Diabetic
Fatty (ZDF) rat [29,30]. Thus, the purpose of the current
study was to investigate some of the possible mechanisms
underlying the protective effects produced by chronic
sitagliptin treatment on pancreatic tissue in the ZDF
rat, focusing on apoptosis, inflammation, angiogenesis
and proliferation mediators.
Methods
Animals and experimental design
Male ZDF rats (ZDF/Gmi, fa/fa) and their littermates
(ZDF/Gmi, +/+) were purchased from Charles River
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and kept in our animal facility until they reached
20 weeks of age. Rats were properly housed, handled
daily, and kept at a controlled standard temperature
(22-23°C), humidity (60%) and light–dark cycles (12/12 h).
Throughout the experiment, the animals were provided
with distilled water ad libitum and rodent maintenance
chow (A-04 Panlab, Barcelona, Spain, containing 15.4% of
protein and 2.9% of lipids). The chow was adapted to the
animal’s body weight (BW): 100 mg/g. Animal experi-
ments were conducted according the European Council
Directives on Animal Care and the National Laws. Along
the text and in order to simplify the description of the
animals, the ZDF/Gmi, fa/fa rats will be designated as
diabetic rats, and, when under sitagliptin treatment, as
sitagliptin-treated diabetic rats. The ZDF/Gmi, +/+ rats
will be designated as lean control or control rats. The
initial groups were established as 15 diabetic rats and
as 10 lean control rats. When aged 20 weeks, n = 5
obese diabetic ZDF rats and the lean control (n = 5)
were sacrificed for blood and tissue collection in order
to establish the basal levels. The remainder lean con-
trol rats followed to week 26, as well as, the diabetic
ZDF rats which were divided in two sub-groups (n = 5
rats each). The sitagliptin-treated group received by
oral gavage, once a day (6:00 PM), during 6 weeks,
10 mg/kg/BW of sitagliptin dissolved in orange juice
(vehicle) and the diabetic untreated group received, in
the same conditions, only the vehicle (orange juice).
The same procedures were adopted with the lean con-
trol rats. At 26 weeks of age, the animals were sacri-
ficed by anaesthetic overdose, blood and tissues were
collected for different analyses.
Glycaemic, insulinaemic and lipidic profile assays
Serum glucose levels were measured using a Glucose
oxidase commercial kit (Sigma, St. Louis, Mo, USA).
Considering the variability of serum glucose levels in the
rat, glycosylated haemoglobin (HbA1c) levels were used
as an index of glucose control, through the DCA 2000+
latex immunoagglutination method (Bayer Diagnostics,
Barcelona, Spain). Plasma insulin levels were quantified
by using a rat insulin Elisa assay kit from Mercodia
(Uppsala, Sweden). The steady state beta cell function
of individual animals was evaluated using the previously
validated homeostasis model assessment (HOMA) of
β-cell function [31]. The formula used was as follows:
[HOMA-β%] = 360 × fasting serum insulin (mU/L)/
fasting serum glucose (mg/dl) − 63. The values used
(insulin and glucose) were obtained after an overnight
of food deprivation. Serum triglycerides (TGs) were
analysed on a Hitachi 717 analyser (Roche Diagnostics)
using standard laboratorial methods. TGs kit was ob-
tained from bioMérieux® (Lyon, France).Endocrine and exocrine pancreas lesions analysis
by histopathology
Sample collection and preparation
The pancreas was immediately removed, placed in ice-
cold Krebs’ buffer and carefully cleaned of extraneous fat
and connective tissue; then the organ was cross-sectioned,
fixed and processed for paraffin embedding in compliance
with the histological protocols used.
Hematoxilyn & eosine staining
Samples were fixed in Bock’s fixative, embedded in par-
affin wax and 3 μm thick sections were stained for rou-
tine histopathological diagnosis with haematoxylin and
eosin (HE). All samples were examined by light micros-
copy using a Microscope Zeiss Mod Axioplan 2. Image
acquisition was performed with digital microscope
camera (Leica DFC450) and image processing was per-
formed with the LAS Advanced Analysis Software
Bundle (No: 12730448.). The degree of injury visible by
light microscopy was scored in a double blind fashion.
Assessment of mean islet number: Islets were counted
using a 10× magnification, in three different micro-
scopic fields and, the mean number per field was calcu-
lated for each study group. Assessment of islet size: Islet
dimensions were obtained by measuring its maximum
girth with an ocular grid of 1000 μm, using a 10× mag-
nification. The maximum diameter was found by com-
paring all available radii diameters of each islet, and
choosing the greatest. Islets were evaluated in three
different microscopic fields and the mean size of the islets
from each group of rats was calculated.
Histopathology
Appreciation of islet architecture was based on the uni-
formity of islet boundaries and classified as regular or ir-
regular. Endocrine pancreatic damage was assessed by
evaluating changes in the islets of Langerhans, namely,
islet architecture (shape), presence of inflammatory infil-
trate, fibrosis, and vacuolization and intra-islet conges-
tion. A semi-quantitative rating for each slide ranging
from 0 (minimal) to 3 (severe and extensive damage)
was assigned to each of the studied components: inflam-
matory infiltrate, congestion, vacuolization and fibrosis.
Each islet was examined and scored. Severity was graded as
0 = absent, 1 =mild, 2 =moderate and 3 = severe. Extension
was evaluated by the area occupied by the lesion, an area
of < 25% of the islet, was scored as 0, an area 25 - 50%
scored as 1, an area 50 - 75% scored as 2, and if detected in
an area > 75% scored as 3. The final score of each sample
was obtained by the average of scores observed in indi-
vidual islets. Exocrine pancreatic damage was evaluated
according to the presence of congestion, fibrosis and
inflammatory infiltrate in the interstitial tissues and graded
also, by the same semiquantitative method, considering the
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Periodic acid of schiff staining
Periodic Acid of Schiff (PAS) was used to confirm the
levels of islet and exocrine fibrosis. Samples were fixed
in neutral formalin 10%, embedded in paraffin wax and
3 μm thick sections were immersed in water and subse-
quently treated with a 1% aqueous solution of periodic acid,
then washed to remove any traces of the periodic acid and
finally treated with Schiff ’s reagent. A semi-quantitative rat-
ing was set for intensity and extension of staining, ranging
from 0 (no staining) to 3 (intense and extensive staining).
Pancreatic protein expression by immunohistochemistry
Formalin-fixed and paraffin embedded tissues were cut
into 3 μm sections and deparaffinised in xylene. 3% H2O2
was used to remove endogenous peroxidase, and citrate
buffered saline (pH 6.0), in MO, was used for antigen
retrieval. Sections were preincubated with normal rabbit
serum to prevent nonspecific binding and then incubated
overnight at 4°C with anti-Bax (Δ 21, 1:50, rabbit polyclonal
antibody, Santa Cruz, Biotechnology), Bcl2 (C 21, 1:50,
rabbit polyclonal antibody, Santa Cruz, Biotechnology) and
TRIB3 (ab22107, 1:100, rabbit polyclonal antibody, Abcam).
The sections were then sequentially incubated at room
temperature, with labelled-(strept)avidin-biotin-peroxidase
method (LAB-SA) (Histostain®-Plus kit Zymed). Negative
controls were included in each staining series, by omission
of the primary antibodies. Positive controls were, respect-
ively for Bax, Bcl2 and TRIB3 canine tonsils, canine breast
carcinoma and the rat exocrine pancreas. Sections were
counterstained with hematoxylin. The results were exam-
ined by light microscopy using a Zeiss Axioplan 2 micro-
scope. Image acquisition and processing was performed
according to described in the previous section. Immuno-
positivity was scored in accordance to staining intensity (I)
and percentage of positive cells (P). Staining intensity was
evaluated as 0, undetectable; 1, weak staining; 2, moderate
staining and 3, intensive staining. Positive cells were
evaluated in all Islets’ of Langerhans present on the
slide. Final scoring for each rat was calculated by the Quick
Score (Q) in which the percentage of positive cells (P) is
multiplied by the intensity (I), using the formula: Q = P × I,
resulting in a score between 0 – 300 [32]. The final score
for each group was found by mean average.
Pancreatic gene (mRNA) expression analysis by RT-qPCR
Sample collection and preparation
The pancreas were immediately collected, placed in
ice-cold Krebs buffer for cleaning of collective tissue
and immediately frozen at −80°C in preservative RNA
later™ solution (Ambion, Austin, TX, USA) until analysis.
Gene (mRNA) expression was evaluated by real-timeRT-qPCR for markers of apoptotic machinery, inflamma-
tion and proliferation/angiogenesis.
Total RNA isolation
Samples were removed from the RNA later™ preservation
solution and 1200 μL of RLT Lysis Buffer was added to
proceed with disruption and homogenization for 2 min at
30 Hz using TissueLyser (Qiagen, Hilden, Germany).
Tissue lysate were processed according to the protocol
from RNeasy® Mini Kit (Qiagen, Hilden, Germany).
Total RNA was eluted in 50 μL of RNase-free water
(without optional treatment with DNAse). In order to
quantify the amount of total RNA extracted and verify
RNA integrity (RIN, RNA Integrity Number), samples were
analysed using 6000 Nano Chip® kit, in Agilent 2100 bioa-
nalyser (Agilent Technologies, Walbronn, Germany) and
2100 expert software, following manufacturer instructions.
The yield from isolation was from 0.5 to 3 μg; RIN values
were 6.0-9.0 and purity (A260/A280) was 1.8-2.0.
Reverse transcription
RNA was reverse transcribed with SuperScript™ III first-
strand synthesis system for RT-PCR (Invitrogen, California,
USA). One microgram of total RNA was mixed with a
2× First-Strand Reaction Mix and a SuperScript™ III
Enzyme Mix (Oligo(dT) plus Random hexamers). Reactions
were carried out in a thermocycler Gene Amp PCR System
9600 (Perkin Elmer, Norwalk, CT, USA), 10 min at 25°C,
50 min at 50°C and 5 min at 85°C. Reaction products were
then digested with 1 μL RNase H for 20 min at 37°C and,
finally, cDNA eluted to a final volume of 100 μL and stored
at −20°C.
Relative quantification of gene expression
Performed using 7900 HT Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA). A
normalization step preceded the gene expression quantifi-
cation, using geNorm Housekeeping Gene Selection kit
for Rattus norvegicus (Primer Design, Southampton, UK)
and geNorm software (Ghent University Hospital, Center
for Medical Genetics, Ghent, Belgium) to select opti-
mal housekeeping genes to this study [33]. Real-time
PCR reactions used specific QuantiTect Primer Assays
(Qiagen, Hilden, Germany) with optimized primers for
Bax, Bcl2, TRB3, IL-1β, PCNA and VEGF. Endogenous
controls were also used: GAPDH, ACTB, TOP1, and
RPL13 together with QuantiTect SYBR Green PCR Kit
Gene expression (Qiagen, Hilden, Germany) according to
manufacturer’s instructions. RT-qPCR reactions were car-
ried out with 100 ng cDNA sample, primers (50–200 nM)
and 1X QuantiTect SYBR Green PCR Master Mix. Non-
template control reactions were performed for each gene,
in order to assure no unspecific amplification. Reactions
were performed with the following thermal profile: 10 min
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Real-time PCR results were analyzed with SDS 2.1 soft-
ware (Applied Biosystems, Foster City, CA, USA) and
quantification used the 2−ΔΔCt method [34].
Statistical analysis
For all biochemical measurements made over time and
treatment effect, independent samples t-Student test was
used. For histopathology and immunohistochemistry
data: Chi-square test with Monte Carlo simulation or exact
test (when contingency tables are 2×2) was performed to
find out the differences in lesions of endocrine/exocrine
pancreas between lean control and diabetic ZDF rats at
the beginning of the study, (20 week-old); untreated and
sitagliptin treated diabetic ZDF and lean control rats at
26 weeks of age. Independent samples t-Student test
was used to determine the differences in the number, re-
gularity and size of the pancreatic islets between lean
control and diabetic ZDF rats in the pre-therapeutic
stage, at 20 weeks; untreated and sitagliptin-treated diabetic
ZDF and lean control ZDF rats at 26 weeks of age. Data
were analysed using SPSS Statistics 20 (2011). For RT-qPCR
data: For statistical analysis, we used the GraphPad Prism,
Version 5.0. Comparisons between groups were performed
using ANOVA and the post-hoc Bonferroni test. All values
are reported as mean ± SEM (standard error of means).
Significance level was accepted at 0.05.
Results
Sitagliptin prevents aggravation of glycaemic,
insulinaemic and lipidic profiles
Concerning body weight, no significant differences were
encountered between the diabetic and the lean control
rats at the beginning of treatments (T0: week 20), des-
pite the obese profile encountered in the diabetic rats
between the 8th and the 14th week (data not shown). At
the end of the study (26 weeks), the untreated diabetic rats
exhibited a reduction in their BW (p < 0.001); nevertheless,
the lean control group gained weight. Sitagliptin treatment,
during 6 weeks, stabilized the loss of weight in the diabetic
ZDF rats, even preventing part of the BW loss when com-
pared with the rats without treatment (Table 1).
At the beginning of treatments (T0: week 20), fasting
blood glucose, HbA1c and TG were already significantly
higher in diabetic rats when compared with their lean
counterparts, indicative of a metabolic deregulation. These
results were accompanied by a decrease in fasting serum
insulin and in the functional ability of the pancreas demon-
strated by the reduction of 87.99% in HOMA-beta values.
An age-dependent increase in the metabolic deregulation
was observed in diabetic untreated ZDF rats presenting
augmented levels of glucose, HbA1c and TG from 20
to 26 weeks old. They also exhibit an aggravation of the
relative insulinopaenia, as well as a decrease in estimatedsteady-state beta cell function (p < 0.001). Six weeks of
sitagliptin treatment was able to significantly ameliorate
all the metabolic parameters as shown in Table 1. In
fact, sitagliptin significantly (p < 0.001) prevented the add-
itional increase in blood glucose and serum TG contents
(16.54% and 37.63%, respectively, vs untreated), while
preventing further decrease in serum insulin and en-
hancing the functional capacity of beta cells (156.28%
and 191.74%, respectively, vs untreated) (Table 1).
Sitagliptin prevents aggravation of endocrine and
exocrine pancreatic damage
Comparative analysis between the endocrine pancreas of
lean control and diabetic ZDF rats of 20 weeks of age re-
vealed a significant increase in inflammation and fibrosis
of Langerhans islets in the diabetic group (p < 0.01), with
no statistically significant differences in the other analyzed
parameters (data not shown). At 26 weeks of age, endocrine
pancreatic inflammation was significantly higher (p < 0.001)
in the diabetic rats when compared with the lean control
animals (Figure 1A, B and G). Sitagliptin-treated dia-
betic ZDF rats showed significantly (p < 0.001) reduced
inflammation when compared with the untreated dia-
betic rats (Figure 1B, C and G). A similar profile was
encountered concerning endocrine pancreatic fibrosis,
which, despite the differences, did not reach statistical
significance (Figure 1D-H).
Concerning the exocrine pancreas lesions, in rats aged
26 week-old, while no significant changes were found
concerning exocrine pancreas inflammation (Figure 2A-C
and G), fibrosis was significantly (p < 0.05) increased in
the diabetic ZDF rats, when compared with the lean
control, which was prevented in the diabetic animals
under sitagliptin therapy (Figure 2D-H).
Cytoprotective effects of sitagliptin against pancreatic
damage progression
Pancreatic tissue mRNA levels of mediators of apoptotic
machinery showed a significantly increased (p < 0.05)
expression of the apoptotic Bax, as well as, antiapoptotic
Bcl2 in the 26 week-old diabetic ZDF rats (Figure 3A and
B, respectively), when compared with the lean ZDF animals,
thus resulting in an unchanged Bax/Bcl2 ratio (Figure 3C).
In the diabetic rats under sitagliptin treatment, there was
an overexpression of the mRNA for both Bax and Bcl2,
favouring a reduced Bax/Bcl2 ratio (Figure 3A-C) as a
result of a higher increment of mRNA expression of
Bcl2 when compared with Bax.
The pancreatic mRNA expression of Bax and Bcl2 was
accompanied by protein expression studies of immuno-
histochemistry (Figure 3D-L). In the untreated diabetic
animals there was a significantly (p < 0.05) rise in Bax
stained cells and unchanged Bcl2, resulting in a trend to
an increased Bax/Bcl2 ratio, when compared with the
Table 1 Body weight and glycaemic, insulinaemic and lipidic profile in the rats under study at the initial and final times
Time Initial time (20 wks old rats) Final time (26 wks old rats)
Groups Control Diabetic Control Diabetic
Parameters Vehicle (n = 10) Vehicle (n = 15) Vehicle (n = 5) Vehicle (n = 5) Sitagliptin (n = 5)
BW (g) 406.70 ± 6.83 388.10 ± 8.87 445.70 ± 8.16 354.40 ± 8.85aaa 380.00 ± 14.46
Glucose (mg/dl) 131.80 ± 1.20 512.00 ± 4.53aaa 133.40 ± 2.16 623.60 ± 7.30bb 520.44 ± 3.31ccc
HbA1c (%) 3.66 ± 0.15 9.96 ± 0.86aaa 3.76 ± 0.26 10.68 ± 0.75 8.68 ± 0.37ccc
Insulin (mU/ml) 14.82 ± 3.90 11.62 ± 1.15aaa 15.13 ± 3.34 7.16 ± 1.14bbb 11.19 ± 1.73ccc
HOMA-Beta (%) 77.70 ± 2.28 9.33 ± 0.83aaa 77.52 ± 1.10 4.60 ± 0.16bbb 8.82 ± 0.32ccc
TGs (mg/dl) 111.60 ± 8.33 366.00 ± 5.92aaa 158.40 ± 6.80 409.80 ± 8.04bb 255.60 ± 3.70ccc
Values are means ± SEM of n rats. Comparisons between groups: aaa = p < 0.001 between diabetic versus control groups (20 or 26 weeks); bb and bbb = p < 0.01 and
p < 0.001, respectively, within the diabetic group (26 versus 20 weeks); ccc = p < 0.001 between diabetic sitagliptin-treated versus diabetic untreated groups
(at 26 weeks).
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for increased protein expression of Bax, accompanied
by a significantly (p < 0.001) increased expression of Bcl2,
which results in a Bax/Bcl2 ratio identical to that found
for the control animals (Figure 3D-L).
Concerning other putative mechanisms behind the
protective effects of sitagliptin on the pancreatic tissue,
we found that the diabetic rats, aged 26 weeks, presented
a significantly increased pancreatic mRNA expression
of IL-1β (p < 0.01), which was prevented (p < 0.001) in
the sitagliptin-treated group (Figure 4A). Sitagiptin was
able to promote overexpression (p < 0.001) of VEGF and
PCNA mRNA when compared with the untreated diabetic
rats (Figure 4B and C, respectively). In addition, sitagliptin
treatment totally (p < 0.001) prevented the diabetes-induced
increment (p < 0.001) in TRIB3 expression in the pancreatic
tissue (Figure 5A-D).
Discussion
Previous studies propose that a disruption of the normal
relationship between insulin sensitivity and pancreatic
β-cell function is crucial for the pathogenesis of T2DM
[4], and that the degeneration of Langerhans islets with
β-cell loss is secondary to insulin resistance and may
have a key role in the progression of the disease [5,6].
Furthermore, the loss of β-cell mass is not yet completely
elucidated, but a possible cause may reside in apoptotic
processes and in a lost capacity for pancreatic regener-
ation [28,35,36]. Previous studies have been suggesting
that gliptins are able to preserve both β-cell function and
cell mass in animal models of diabetes [29,37-39], but the
mechanisms underlying the protective effects remain to
be elucidated.
Consistent with previous reports our study demon-
strated that a 6 weeks sitagliptin treatment was able to
improve β-cell function as well as preserve pancreatic
islet structure. We hypothesize that sitagliptin is able to
preserve pancreatic function by improving insulin resist-
ance and by other cytoprotective properties, includingantiapoptotic, anti-inflammatory and pro-proliferative,
based on the cytoprotective properties previously reported
for incretin peptides in distinct tissues [29,37-43]. In fact,
the results presented herein strongly suggest that in diabetic
ZDF rats sitagliptin may derive its cytoprotective effects via
two different type of influences: directly reducing apoptosis
and promoting cell proliferation due to increase incretin
availability; indirectly via metabolic effects, including ameli-
oration of chronically elevated glucose and triglycerides,
prevention of insulinopaenia and reduction of inflamma-
tion, thus protecting from deleterious effects derived from
glucotoxicity, lipotoxicity and insulin resistance.
The histomorphological evaluation of endocrine and
exocrine pancreatic tissue shows that the differences
between diabetic untreated and sitagliptin-treated animals
were striking. In fact, the sitagliptin-treated rats presented
an amelioration of inflammation and fibrosis in endocrine
and exocrine pancreas. In particular, inflammation was
highly reduced in the islets of Langerhans, and the
exocrine pancreas of diabetic rats receiving sitagliptin
did not present fibrotic changes in the vascular and the
ductal walls. The changes described above were repeat-
edly and systematically observed by two pathologists
unaware of the identity of the slides. These findings are in
accordance with our preliminary work [29] but in contra-
diction with the results obtained by Matveyenko et al. [37]
using a DPP IV inhibitor in human IAPP transgenic (HIP)
rats and by Nachnani et al. [41] using an injection of GLP-1
agonist, who suggest that the enhancement of endogenous
GLP-1 levels could induce undetected low grade asymp-
tomatic chronic pancreatitis. The histomorphological
observations were in accordance with an improvement
in pancreatic beta-cell function as shown by the augmenta-
tion in HOMA-beta in diabetic sitagliptin-treated rats. The
effects of chronic inhibition of DPP-IV in increasing β-cell
mass and function over time could be due, at least in part,
by the increase in glucose-stimulated insulin secretion,
which is believed to be mediated primarily via stabilization
of the incretin hormones, including GLP-1 [27].
Figure 1 Sitagliptin effects on inflammation and fibrosis of endocrine pancreas of diabetic ZDF rats. Endocrine inflammation in 26 week-old
animals (images A-C): (A) Micrograph of normal islet of Langerhans observed in a lean control ZDF rat; (B) Islet of Langerhans of an untreated diabetic
ZDF rat showing severe inflammatory infiltrate occupying over 50% of the islet’s area (Grade 3 inflammation); (C) A clearly regression of inflammation is
observed after 6 weeks of sitagliptin treatment in obese diabetic ZDF rat (Grade 1 inflammation). Endocrine fibrosis observed in 26 week-old animals
(images D-F): (D) Normal islet of Langerhans of lean control ZDF rat; (E) Grade 3 fibrosis in an untreated obese diabetic ZDF rat, displaying a large and
irregularly shaped islet filled with fibrous tissue, evidenced by intense pink staining; (F) Grade 1 fibrosis in a regular, small islet in sitagliptin treated diabetic
ZDF rats. Semiquantitative evaluation of inflammation (graph G) and fibrosis (graph H): (G) A significantly higher (p< 0.001) endocrine inflammation in
diabetic rats was recorded when compared to lean control animals. Sitagliptin treatment of diabetic ZDF rats during 6 weeks significantly reduced
(p< 0.001) inflammation in comparison to untreated counterparts; (H) Data for endocrine fibrosis showed a trend for an increase in diabetic rats when
compared to lean control animals, and a trend for improvement with sitagliptin treatment, although without statistical significance. Chi-square test with
Monte Carlo simulation or exact test (when contingency tables are 2 × 2) was performed to find out the differences in histomorphological lesions
observed in endocrine pancreas. (p< 0.05, p< 0.01 and p< 0.001 for one, two or three symbols, respectively; n = 5 per group).
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Figure 2 Sitagliptin effects on inflammation and fibrosis of exocrine pancreas of diabetic ZDF rats. Histopathological observation of
exocrine inflammation in 26 week-old animals (images A-C): (A) Micrograph of a normal exocrine parenchyma of lean control ZDF rat; (B) The
untreated diabetic rats exhibiting severe inflammatory infiltrate, amid the acini of the exocrine parenchyma (grade 3 inflammatory lesions);
(C) Normal exocrine parenchyma with no inflammatory signs in the exocrine pancreas of sitagliptin-treated diabetic ZDF rats. Histopathological
observation of exocrine fibrosis in 26 week-old animals (images D-F): (D) Normal pancreatic duct in a lean control ZDF rat; (E) An extremely
thickened, grade 3, fibrotic duct, which overextends the microscopic field (interrupted line), with numerous neocanaliculi in the duct wall, .present
in an untreated diabetic ZDF rat; (F) Improvement of duct fibrosis from grade 3 to grade 1 (full line) in a 6 weeks sitagliptin treated diabetic ZDF
rat. Semiquantitative evaluation of inflammation (graph G) and fibrosis (graph H): (G) Exocrine pancreatic inflammation revealed only a slight
descent in sitagliptin treated animals in relation to its untreated counterparts; (H) Sitagliptin presented a trend to decrease the duct fibrosis
increment (p < 0.05) found in the untreated ZDF rats. Chi-square test with Monte Carlo simulation or exact test (when contingency tables are 2×2) was
performed to find out the differences in histomorphological lesions observed in exocrine pancreas (p < 0.05, p < 0.01 and p < 0.001 for one, two or
three symbols, respectively; n = 5 per group).
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Figure 3 (See legend on next page.)
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Figure 3 Sitagliptin protects the diabetic ZDF rats against endocrine pancreas apoptotic cell death. Upper panel (A-C) - pancreas mRNA
expression of Bax and bcl2 in 26 week-old ZDF rats: A significant increase (p < 0.05) in apoptotic protein Bax (A), as well as, in antiapoptotic Bcl2
(B) was observed in the untreated diabetic ZDF rats when compared with the lean control ZDF animals, resulting in an unchanged Bax/Bcl2 ratio
(C). In the sitagliptin-treated diabetic rats an overexpression of the mRNA was registered for both Bax (not statically significant) and Bcl2 (p < 0.001)
ensuing a reduced Bax/Bcl2 ratio (C). Middle panel (D-I) - Immunostaining of pancreas Bax and Bcl2 in 26 week-old ZDF rats: (D) The expression of
Bax protein is not present in the pancreatic islet (grade 0) of a lean control rat; (E) A deeply stained islet (grade 3) revealing Bax protein expression
in untreated diabetic ZDF rat; (F) The diabetic sitagliptin-treated rats displayed a light stained islet (grade 1); (G) Expression of Bcl2 protein not
observed in islet (grade 0) of a lean control rat; (H) A moderately stained islet (grade 2) with Bcl2 antibody in an untreated diabetic ZDF rat; (I) An
intensely stained islet (grade 3) in a diabetic sitagliptin-treated rat. Lower panel (J-L) - Quantification of protein expression: Bax protein expression
in diabetic untreated rats exhibited a significant increase in relation to lean control rats; in sitagliptin-treated diabetic rats, Bax presented a trend for
overexpression (J), accompanied by a significantly (p < 0.001) increased expression of Bcl2 (K), resulting in a Bax/Bcl2 ratio identical to control
animals (L). Statistical comparisons between groups were performed using one-way ANOVA and the post-hoc Bonferroni test (p < 0.05, p < 0.01 and
p < 0.001 for one, two or three symbols, respectively; n = 5 per group).
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http://www.dmsjournal.com/content/6/1/42It is well established that apoptosis is one of the pathways
responsible for the progressive deterioration of beta cell
and evolution of diabetes. Our study suggests that sitaglip-
tin is able to promote an antiapoptotic effect, which is in
agreement with other reports [37-40,44] in the pancreatic
tissue. In fact, Matveyenko et al. [36] reported that sita-
gliptin therapy led to preservation of β-cell mass in HIP
rats as compared with its untreated counterparts, while
Maida et al. [38] reported an increment of percentage of
β-cell area in streptozotocin-induced diabetic mice under
sitagliptin treatment. The antiapoptotic properties of sita-
gliptin is also in agreement with the effects reported in
extra-pancreatic tissues, such as the kidney, with improve-
ment of renal function and reduction of parenchymal
damage, due to a decrease in apoptosis, inflammation and
an increase of in antioxidant capacity [30,40,45,46]. Apart
from the antiapoptotic effect suggested by our results,
the protective effects afforded by sitagliptin on the pan-
creas tissue might be the result of other activities previ-
ously described for the incretin peptides, including GLP-1
[15,16,47-51]. Anti-inflammatory, pro-angiogenic and
pro-proliferative properties are suggested by the reduced
expression of IL-1β and by the increased expression of
VEGF and PCNA observed in the pancreas tissue ofFigure 4 Effects of sitagliptin treatment on pancreatic mRNA express
IL-1β, VEGF and PCNA. (A) mRNA expression of pancreatic IL-1β in untrea
to lean control rats; in the sitagliptin-treated diabetic group, overexpression
(p < 0.001) of VEGF (B) and PCNA (C) mRNA in ZDF diabetic rats treated wi
Statistical comparisons between groups were performed using one-way AN
for one, two or three symbols, respectively; n = 5 per group).sitagliptin-treated diabetic rats. Inflammation has been
associated with the development of insulin resistance,
beta cell apoptosis and evolution of diabetes, and IL-1β
is one of the main inflammatory cytokines in the
process [52,53]. We and other authors have suggested
anti-inflammatory properties of gliptins in distinct ani-
mal models and tissues, as well as, in type 2 diabetic
patients [29,43,45,54-56], in agreement with our hy-
pothesis. VEGF is expressed in the endocrine cells and
the increased VEGF expression found in the diabetic
rats under sitagliptin treatment might be viewed as an
increased capacity for tissue regeneration. The same is
true for PCNA, which is an indicator for cell proliferation
and has been used in the present work to determine β-cell
mass expansion [57,58]. It could be hypothesized that
sitagliptin-evoked increased GLP-1 availability, due to
inhibition of its degradation by DPP-IV, will favour the
development of new cells, via proliferation enhancement of
pre-existing cells and induction of islet neogenesis, effects
that were previously reported for GLP-1 [27].
The second mechanism involved in the effect of sita-
gliptin may be related to significant improvement in the
metabolic profile, including amelioration of glucose, in-
sulin and TGs levels. We must empathize that the doseion of mediators of inflammation, angiogenesis and proliferation:
ted diabetic ZDF rats was significantly increased (p < 0.01) in contrast
of IL-1β was significantly prevented (p < 0.001). Overexpression
th sitagliptin for 6 weeks when compared with untreated diabetic rats.
OVA and the post-hoc Bonferroni test (p < 0.05, p < 0.01 and p < 0.001
Figure 5 Sitagliptin prevents TRIB3 protein overexpression in
pancreas of ZDF diabetic rats. Micrographs of TRIB3 expression by
immunostaining in 26 week-old ZDF rats (A-C): (A) Lean ZDF control
rat presenting unstained pancreatic islet (grade 0); (B) Untreated
diabetic ZDF rat showing an intensely stained pancreatic islet
(grade 3); (C) Sitagliptin-treated diabetic rat for 6 weeks displayed light
staining of endocrine cells (grade 1). Exocrine pancreatic tissue presents
normal constant staining for TRIB3 in all three groups. (D) Quantification
of protein expression by score points: expression of TRIB3 is almost
undetectable in control rats, rising very significantly (p < 0.001) in
untreated diabetic ZDF rats; and declining very meaningfully (p < 0.001)
in 6 weeks sitagliptin-treated diabetic treated rats. Statistical comparisons
between groups were performed using one-way ANOVA and the
post-hoc Bonferroni test (p< 0.05, p< 0.01 and p< 0.001 for one, two or
three symbols, respectively; n = 5 per group).
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http://www.dmsjournal.com/content/6/1/42of sitagliptin used in our study (10 mg/kg/day) may be
considered a low dose as others have used higher doses
or a twice a day treatment [37,38,40]. Nevertheless, sitaglip-
tin treatment improved hyperglycaemia and hypertriglyceri-
daemia, thus ameliorating glucolipotoxicity in the diabetic
ZDF rats. Several pathophysiological mechanisms have
been identified as potential contributors to β-cell stress
and subsequent dysfunction, including glucotoxicity,
lipotoxicity, and increased secretory demand resulting
from insulin resistance. In addition, disturbances in secre-
tion of various adipose tissue-secreted factors or cytokines
derived from the innate immune system might also play a
causal role [18]. Furthermore, both hyperglycaemia and
hyperlipidaemia are associated with induction of oxidative
stress in β-cells. Previously, we have already demonstrated
using this animal model that a low-dose chronic sitagliptin
treatment was able to promote a favourable impact on
chronic inflammation and oxidative stress [29]. In this
context, it should also be noted that the effect of liraglutide
upon endoplasmatic reticulum stress, oxidative stress and
cell apoptosis in diabetic db/db rats, as well as the results of
vildagliptin in diabetic KK-Ay mice, are essentially compat-
ible with those observed in this study [59,60].
Malfunctioning insulin secretion and/or insulin resist-
ance are recognized as key factors for the pathogenesis
of T2DM [61,62]; the latter results from anomalies in the
insulin signaling cascade, a regulated complex molecular
pathway, which may be inhibited and activated by many
biochemical mechanisms [62]. One of the genes impli-
cated in coding inhibitors of insulin signaling and action is
TRIB3, a mammalian tribbles homolog that binds Akt
inhibiting downstream insulin-signalling cascade [62,63].
Our current study revealed that 26 week old ZDF diabetic
rats showed pancreas overexpression of TRIB3 which,
concurrently, showed insulin resistance and relative
insulinopaenia. Sitagliptin treatment was able to com-
pletely reduce tissue TRIB3 expression, which might be
a key mechanism for the decline of insulin resistance
and improvement of insulin secretion observed in the
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http://www.dmsjournal.com/content/6/1/42diabetic rats under sitagliptin treatment. It has been
shown, in cellular and animal models, that changes in
TRIB3 expression levels induce systemic insulin resistance
[64-66]. Indeed, increased TRIB3 expression was observed
in islets from T2DM donors and high fed diet (HFD) mice
[61,63]. In humans, TRIB3 has also been associated with
insulin resistance and T2DM, accompanied by enhanced
inhibition of insulin signalling and AKT/PKB activation
in different tissues, including the β cells [61,67,68]. Prior
rodent studies [64-66,69], indicate that TRIB3 overex-
pression plays a major role in modulating whole-body
insulin sensitivity and suggest a possible involvement in
the pathogenesis of insulin resistance-related metabolic
abnormalities. Another pivotal aspect by which TRIB3
seems to be associated with the evolution of insulin resist-
ance and pancreas degradation is its role in inducing apop-
tosis in pancreatic β-cells and inhibiting cell proliferation;
so, by downregulating the expression of TRIB3, sitagliptin
promotes antiapoptotic effects and enhance β-cell prolifera-
tion, thus contributing to the beneficial effects afforded by
this DPP-IV inhibitor in this animal model.Conclusions
In this animal model of obese type 2 diabetes (the ZDF rat)
sitagliptin prevented β-cell dysfunction and evolution
of pancreas damage. The protective effects afforded by
this DPP-IV inhibitor may derive from improvement of
metabolic profile (related to amelioration of glycaemic
and lipidic levels and of insulin resistance) and from
cytoprotective properties. In fact, sitagliptin was able
to reduce Bax/Bcl2 ratio, suggestive of an antiapoptotic
effect, and completely prevented the increased pancreas
overexpression of IL-1β and TRIB3 found in the untreated
diabetic animals, thus demonstrating an anti-inflammatory
action; in addition, sitagliptin was able to promote overex-
pression of VEGF and PCNA, suggesting pro-angiogenic
and pro-proliferative properties. From a therapeutic
viewpoint, our results reinforce the status of sitagliptin
as a promising antidiabetic drug not only by the ex-
pected glycaemic control but also, and specially, by the
ability to prevent the decline of insulin secreting cap-
acity in pancreatic islets through tissue-cytoprotective
properties, thus suggesting a role in the prevention of
diabetes evolution.
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